Xilio reports handful of responses for combo in colorectal cancernews2025-01-22T16:20:38+00:00January 22nd, 2025|Endpoints News|
Tris Pharma declares Phase 3 win for ‘opioid-like’ painkiller. Can it sell?news2025-01-22T13:30:55+00:00January 22nd, 2025|Endpoints News|
Inhibrx’s early colorectal cancer data clouded by patient deathnews2025-01-22T12:18:49+00:00January 22nd, 2025|Endpoints News|
Regeneron CSO George Yancopoulos on AI’s hype and potentialnews2025-01-22T12:00:06+00:00January 22nd, 2025|Endpoints News|
GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?news2025-01-22T11:56:54+00:00January 22nd, 2025|Endpoints News|
China’s drug development explosion forces a US biotech reckoningnews2025-01-21T15:30:24+00:00January 21st, 2025|Endpoints News|
With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer’s drugnews2025-01-21T15:00:40+00:00January 21st, 2025|Endpoints News|
FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefitnews2025-01-17T19:46:40+00:00January 17th, 2025|Endpoints News|
Novo claims high-dose Phase 3 Wegovy win but sales impact might be mutednews2025-01-17T15:23:48+00:00January 17th, 2025|Endpoints News|
AstraZeneca wins BTK race to market in first-line mantle cell lymphomanews2025-01-17T12:02:32+00:00January 17th, 2025|Endpoints News|
